Medulloblastomas: New directions in risk stratification

Neurology India

Volumn 54, Issue 1, 2006, Pages 16-23

  Sarkar, Chitra ^a   Deb, Prabal ^a   Sharma, Mehar Chand ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Histopathology; Medulloblastoma; Molecular genetics; Prognostic factors; Risk stratification

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; BRAIN DERIVED GROWTH FACTOR; COLLAGEN TYPE 5; CYTOCHROME C OXIDASE; ELASTIN; ENOLASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NERVE GROWTH FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; SODIUM CHANNEL; SONIC HEDGEHOG PROTEIN; SORCIN; WNT PROTEIN;

AGE; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 17Q; CLINICAL PRACTICE; COGNITIVE DEFECT; GENE EXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LABELING INDEX; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PLOIDY; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

EID: 33646745761     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.24696     Document Type: Review

References (130)

1. Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IAHC Press; 2000. p. 6-7.
2. Arseni C, Ciurea AV. Statistical survey of 276 cases of medulloblastoma (1935-1978). Acta Neurchir (Wien) 1981;57:159-62.
3. Farwell JR, Dohrmann GJ, Flannery JT. Medulloblastoma in childhood: an epidemiologieal study. J Neurosurg 1984;61:657-64.
4. Giangaspero F, Bigner SH, Kleihues P, Pietsch T, Trojanowski JO. Medulloblastoma. In: Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 129-37.
5. Roberts RO, Lynch CF, Jones MP, Hart MN. Medulloblastoma: a population-based study of 532 cases. J Neuropathol Exp Neurol 1991;50:134-44.
6. Sarkar C, Pramanik P, Karak AK, Mukhopadhyay P, Sharma MC, Singh VP, et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J Neurooncol 2002;59:49-61.
7. Ferrante L, Mastronardi L, Celli P, Acqui M, Cervoni L, Fortuna A. Medulloblastoma in adulthood. J Neurosurg Sci 1991;35:23-30.
8. Giordana MT, Schiffer P, Lanotte M, Girardi P, Chio A. Epidemiology of adult medulloblastomas. Int J Cancer 1999;80:689-92.
9. Hubbard JL, Scheithauer BW, Kispert DB, Carpenter SM, Wick MR, Laws ER. Adult cerebellar medulloblastomas: the pathological, radiographic and clinical disease spectrum. J Neurosurg 1989;70:536-44.
10. Muleci A, Cervoni L, Delfini R. Medulloblastomas in children and in adults:a comparative study. Acta Neurochir (Wien) 1992;119:62-7.
11. Pramanik P, Sharma MC, Mukhopadhyay P, Singh VP, Sarkar C. A comparative study of classical vs. desmoplastic medulloblastomas. Neurol India 2003;51:27-34.
12. Chang CH, Housepian EM, Herbert C. An operative staging system and a megavoltage radiotherpeutic technic for cerebellar medulloblastoma. Radiology 1969;93:1351-69.
13. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children:Conclusions from the Children's Cancer Group 921 randomized phase II study. J Clin Oncol 1999;17:832-45.
14. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-85.
15. Kortmann RD, Kuhl J, Timmerman B, Mittler U, Urban C, Budach V, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT'91. Int J Radit Oncol Biol Phys 2000;46:269-79.
16. Saran F. Recent advances in paediatric neuro-oncology. Curr Opin Neurol 2002;15:671-7.
17. Brandes AA, Palmisano V, Monfardini S. Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 1999;25:3-12.
18. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93.
19. Heikens J, Michiels EM, Behrendt H, Endert E, Bakker PJ, Fliers E. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 1998;34:1592-7.
20. Walter AW, Mulhern RK, Gajjar A, Heideman RL, Reardon D, Sanford RA, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol 1999;17:3720-8.
21. Mulhern RK, Palmer SL, Reddick WE, Glass JO, Kun LE, Taylor J, et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 2001;19:472-9.
22. Ironside JW, Moss TH, Louis DN, Lowe JS, Weller RO (editors). Embryonal tumours. In: Diagnostic pathology of nervous system tumours. London: Churchill Livingstone; 2002. p. 185-215.
23. th edn. Philadelphia: Churchill Livingstone; 2002. p. 298-338.
24. Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R, et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 1999;91:971-7.
25. Giangaspero F, Rigobello L, Badiali M, Loda M, Andreini L, Basso G, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992;16:687-93.
26. Kalimo H, Haapasalo H. Melanotic medulloblastoma. In: Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 140.
27. Sharma MC, Agarwal M, Suri A, Gaikwad S, Mukhopadhyay P, Sarkar C. A melanotic desmoplastic medulloblastoma: report of a rare case and review of the literature. Brain Tumor Pathol 2002;19:93-6.
28. Chowdhury C, Roy S, Mahapatra AK, Bhatia R. Medullomyoblastoma. A teratoma. Cancer 1985;55:1495-500.
29. Giordana MT, Wiestler OD. Medullomyoblastoma. In: Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 138-9.
30. Lata M, Mahapatra AK, Sarkar C, Roy S. Medullomyoblastoma. A case report. Indian J Cancer 1989;26:240-6.
31. Mahapatra AK, Sinha AK, Sharma MC. Medullomyoblastoma. A rare cerebellar tumour in children. Childs Nerv Syst 1998;14:312-6.
32. Suresh TN, Santosh V, Yasha TC, Anandh B, Mohanty A, Indiradevi B, et al. Medulloblastoma with extensive nodularity: a variant occurring in the very young-clinicopathological and immunohistochemical study of four cases. Childs Nerv Syst 2004;20:55-60.
33. MacManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, et al. Morphophenotypic variation predicts clinical behaviour in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 2003;62:627-32.
34. Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995;25:166-78.
35. Chatty EM, Earle KM. Medulloblastoma. A report of 201 cases with emphasis on the relationship of histological variants to survival. Cancer 1971;28:977-83.
36. Jeukin D, Shabanah MA, Shail EA, Gray A, Hassounah M, Khafaga Y, et al. Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 2000;47:573-84.
37. Giordana MT, Cavalla P, Chio A, Marino S, Soffietti R, Vigliani MC, et al. Prognostic factors in adult medulloblastoma. A clinico-pathologic study Tumori 1995;81:338-46.
38. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-60.
39. Garton GR, Schomberger PJ, Scheithauer BW, Shaw EG, Ilstrup DM, Blackwell CR, et al. Medulloblastoma: Prognostic factors and outcome of treatment:review of the Mayo Clinic experience. Mayo Clin Proc 1990;65:1077-86.
40. Beckwith JB. National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol 1998;1:79-84.
41. Brown HG, Kepner JL, Perlman EJ, Friedman US, Strother DR, Duffner PK, et al. "Large cell/anaplastic" medulloblastomas:a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000;59:857-65.
42. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 2002;28:257-82.
43. Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, et al. Large cell/ anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001;95:82-8.
44. Eberhart CG, Cohen KJ, Tihan T, Goldthwaite PT, Burger PC. Medulloblastomas with systemic metastases: evaluation of tumor histopathology and clinical behavior in 23 patients. J Pediatr Hematol Oncol 2003;25:198-203.
45. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
46. Sarkar C, Roy S, Tandon PN. Primitive neuroectodermal tumours of the central nervous system - an electron microscopic and immunohistochemical study. Indian J Med Res 1989;90:91-102.
47. Caputy AJ, McCullough DC, Manz HJ, Patterson K, Hammock MK. A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 1987;66:80-7.
48. Goldberg-Stern H, Gadoth N, Stern S, Cohen IJ, Zaizox R, Sandbank U. The prognostic significance of glial fibrillary acidic protein staining in medulloblastoma. Cancer 1991;68:568-73.
49. Janss AJ, Yachnis AT, Silber JH, Trojanowski JQ, Lee VM, Sutton LN, et al. Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors. Ann Neurol 1996;39:481-9.
50. Packer RJ, Sutton LN, Rorke LB, Littman PA, Sposto R, Rosenstock JG, et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984;61:296-301.
51. Coffin CM, Braun JT, Wick MR, Dehner LP. A clinicopathologic and immunohistochemical analysis of 53 cases of medulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990;3:164-70.
52. Verma A, Sarkar C, Bhatia R, Banerji AK, Mehta VS, Mahapatra AK. Retrospective study of medulloblastoma with special reference to astrocytic differentiation - review of 63 cases. Neurol India 1993;41:7-12.
53. Ito S, Hoshino T, Prados MD, Edwards MH. Cell kinetics of medulloblastomas. Cancer 1992;70:671-8.
54. Schiffer D, Cavalla P, Migheli A, Chio A, Giordana MT, Marino S, et al. Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 1995;195:81-4.
55. Haslam RH, Lamborn KR, Becker LE, Israel MA. Tumor cell apoptosis present at diagnosis may predict treatment outcome for patients with medulloblastoma. J Pediatr Hematol Oncol 1998;20:520-7.
56. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 1999;16:37-44.
57. Korshimov A, Savostikova M, Ozerov S. Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC and c-myc expression. J Neuro Oncol 2002;58;271-9.
58. Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H, Brodeur GM. Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. Eur J Cancer 2002;38:92-8.
59. Ramachandran C, Khatib Z, Escalon E, Fonseca HB, Jhabvala P, Medina LS, et al. Molecular studies in pediatric medulloblastomas. Brain Tumor Pathol 2002;19:15-22.
60. Brandes AA, Paris MK, Basso U. Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments? Expert Rev Anticancer Ther 2003;3:615-20.
61. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003;7:53-66.
62. Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones-Wallace D, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-12.
63. Gilbertson R. Paediatric embryonic brain tumours biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002;38:675-85.
64. Fisher PG, Burger PC, Eberhart CG. Biologic risk stratification of medulloblastoma: the real time is now. J Clin Oncol 2004;22:1-4.
65. Packer RJ, Rood BR, Mac Donald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003;39:60-7.
66. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004;5:209-18.
67. Cogen PH, Mc Donald JD. Tumour suppressor genes and medulloblastoma. J Neurooncol 1996;29:103-12.
68. McDonald JD, Daneshvar L, Willert JR, Matsumura K, Waldman F, Cogen PH. Physical mapping of chromosome 17p13.3 in the region of a putative tumour suppressor gene important in medulloblastoma. Genomics 1994;23:229-32.
69. Nicholson JC, Wickramasinghe CL, Ross FM, Crolla J, Ellison DW. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol Path 2000;53:313-9.
70. Scheurlen WG, Seranski P, Minchera A, Kuhl J, Sorensen N, Krauss J, et al. High resolution deletion mapping of chromosome arm 17p in childhood primitive neuroectodermal tumours reveals a common chromosomal disruption within the Smith-Magenis Region, an unstable region in chromosome band 17p11.2. Genes Chromosomes Cancer 1997;18:50-8.
71. Steichen-Gersdorf E, Baumgartener M, Kerczy A, Maier H, Fink FM. Deletion mapping on chromosome 17p in medulloblastomas. Br J Cancer 1997;76:1284-7.
72. Biegel JA, Janss AJ, Raffel C, Sutton L, Rorke LB, Harper JM, et al. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system. Clin Cancer Res 1997;3:473-8.
73. Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 1988;30:91-101.
74. Vagner C, Zattara C, Gambarelli D, Gentet JC, Genitori L, Lena G, et al. Detection of i(17q) chromosome by fluorescent in situ hybridisation (FISH) with interphase nuclei in medulloblastoma. Cancer Genet Cytogenet 1994;78:1-6.
75. Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, et al. Prognostic implications of chromosome 17p deletions in human medulloblastoma. J Neurooncol 1995;24:39-45.
76. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumours defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-85.
77. Emadian SM, Mc Donald JD, Gerken SC, Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res 1996;2:1559-64.
78. Adesina AM, Nalbantoglu J, Cavenee WK. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994;54:5649-51.
79. Saylors P, Sidransky D, Friedman H, Bigner S, Bigner D. Infrequent p53 gene mutations in medulloblastoma. Cancer Res 1991;51:4721-3.
80. Woodburn RT, Azzarelli B, Montebello JF, Goss IE. Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol 2001;52:57-62.
81. Rod BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res 2002;62:3794-7.
82. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-4.
83. Avet-Loiseau H, Venuat AM, Terrier-Laeombe MJ, Lellouch-Tubiana A, Zerah M, Vassal G. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer 1999;79:1843-7.
84. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Galassi E, et al. N-myc and c-myc oncogenes amplification in medulloblastoma. Evidence of particularly aggressive behaviour of a tumour with c-myc amplification. Tumouri 1991;77:118-21.
85. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-50.
86. Jay V, Squire J, Bayani J, Alkhani AM, Rutka JT, Zielenska M. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology 1999;31:337-44.
87. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T, et al. C-MYC expression in medulloblastoma and its prognostic value. Int. J Cancer 2000;89:395-402.
88. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
89. Bruggers CS, Tai KF, Murdock T, Sivak L, Le K, Perkins SL, et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 1998;20:18-25.
90. Moriuchi S, Shimizu K, Miyao Y, Hayakawa T. An immunohistochemical analysis of medulloblastoma and PNET with emphasis on N-myc protein expression. Anticancer Res 1996;16:2687-92.
91. Blaeker H, Rasheed BK, McLendon RE, Friedman HS, Batra SK, Fuchs HE, et al. Microsatellite analysis of childhood brain tumours. Genes Chromosome Cancer 1996;15:54-63.
92. Kraus JA, Koch A, Albrecht S, von Deimling A, Wiestler OD, Pietsch T. Loss of heterozygosity at locus F 13B on chromosome 1 Q in human medulloblastoma. Int J Cancer 1996;67:11-5.
93. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridisation. Cancer Res 1997;57:4042-7.
94. Thomas GA, Raffel C. Loss of heterozygosity on 6q, 16q and 17p in human central nervous system primitive neuroectodermal tumors. Cancer 1991;51:639-43.
95. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 2002;62:5906-11.
96. Tong CY, Hui AB, Yin XL, Pang JC, Zhun XL, Poon WS, et al. Detection of oncogenes amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg Spine 2004;100:187-93.
97. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.
98. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
99. Barbacid M. Neurotropic factors and their receptors. Curr Opin Cell Biol 1995;7:148-55.
100. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
101. Minichiello L, Klein R. TrkB and TrkC neurotrophin receptors cooperate in promoting survival of hippocampal and cerebellar granule neurons. Genes Dev 1996;10:2849-58.
102. Tajima Y, Molina RP Jr, Rorke LB, Kaplan DR, Radeke M, Feinstem SC, et al. Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors. Acta Neuropathol (Berl) 1998;95:325-32.
103. Washiyama K, Muragaki Y, Rorke LB, Lee VM, Feinstein SC, Radeke MJ, et al. Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. Am J Pathol 1996;148:929-40.
104. Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SL. Expression of the neurotrophin receptor TrkC is linked to a favourable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994;91:12867-71.
105. Kim JY, Button ME, Lu DJ, Oho TA, Goumnerova LC, Goritchenko L, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999;59:711-9.
106. Grotzer MA, Janss AJ, Fung K, Biegel JA, Sutton LN, Rorke LB, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumours. J Clin Oncol 2000;18:1027-35.
107. Gilbertson RJ, Clifford HC, MacMeekin W, Meekin W, Wright C, Perry RH, et al. Expression of the ErbB-neuregulin signalling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998;58:3932-41.
108. Rio C, Rieff HI, Qi P, Khurana TS, Corfas G. Neuregulin and ErbB receptors play a critical role in neuronal migration. Neuron 1997;19:39-50.
109. Gilbertson RJ, Jaros EB, Perry RH, Pearson AD. Prognostic factors in medulloblastoma. Lancet 1992;340:480.
110. Gilbertson RJ, Pearson AD, Peny RH, Jaros E, Kelly PJ. Prognostic significance of the c-ErbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995;71:473-7.
111. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80.
112. Herms JW, Behnke J, Bergmann JM, Christen HJ, Kolb R, Wilkening M, et al. Potential prognostic value of C-ErbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 1997;19:510-5.
113. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999;22:103-14.
114. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homologue of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51.
115. Dean M. Polarity, proliferation and the hedgehog pathway. Nat Genet 1996;14:245-7.
116. Reifenberger GJ, Wiestler OD, Chenevix-Trench G. NBCSS. In: Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 240-1.
117. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-5.
118. Vorechovsky I, Tingby O, Hartman M, Stromberg B, Nister M, Collins VP, et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997;15:361-6.
119. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G. Mutations in the human homologue of the Drosophilia segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumours of the central nervous system. Cancer Res 1997;57:2581-5.
120. Evans DG, Farndon PA, Burnell LD, Gattamaneni HR, Birch JM. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991;64:959-61.
121. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of the Drosophilia patched. Cancer Res 1997;57:2085-8.
122. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998;8:573-81.
123. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 2000;10:392-9.
124. Eberhart CG, Tihan T, Burger PC. Nuclear localisation and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000;59:333-7.
125. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, et al. APC mutations in sporadic medulloblastomas. Am J Pathol 2000;156:433-7.
126. Mori T, Nagase H, Horii A, Miyoshi Y, Shimano T, Nakatsuru S, et al. Germ-line and somatic mutations of the APC gene in patients with Turcot syndrome and analysis of APC mutations in brain tumours. Genes Chromosomes Cancer 1994;9:168-72.
127. Zurawel RH, Allen C, Chiappa S, Cato W, Biegel J, Cogen P, et al. Analysis of PTCH/ SMO/SHH pathway genes in medulloblastoma. Genes Chromosome Cancer 2000;27:44-51.
128. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998;58:896-9.
129. Cavenee WK, Burger PC, van Meir EG. Turcot syndrome. In: Kleihues P, Cavenee WK (editors). World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000. p. 238-9.
130. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406:1005-9.